Dexamethasone increases plasma levels of albendazole

Area of Science:

• Neuroparasitology
• Pharmacology
• Clinical Medicine

Background:

• Neurocysticercosis treatment with cysticidal drugs can cause symptom exacerbation due to inflammation from parasite destruction.
• Dexamethasone effectively manages these inflammatory adverse reactions.
• However, dexamethasone reduces the efficacy of praziquantel, another cysticidal drug, by lowering its plasma levels.

Purpose of the Study:

• To investigate the effect of simultaneous dexamethasone administration on the plasma levels of albendazole, a key cysticidal drug for neurocysticercosis.
• To determine if concurrent treatment with albendazole and dexamethasone is feasible without compromising cysticidal efficacy.

Main Methods:

• Plasma levels of albendazole were measured in patients receiving both albendazole and dexamethasone concurrently.
• Statistical analysis was performed to determine the significance of changes in albendazole plasma levels.

Main Results:

• Dexamethasone significantly increased plasma levels of albendazole by approximately 50% (P < 0.002).
• This indicates a pharmacokinetic interaction where dexamethasone enhances albendazole bioavailability.

Conclusions:

• Simultaneous treatment of neurocysticercosis and associated inflammation with albendazole and dexamethasone appears to be safe and effective.
• The observed increase in albendazole levels suggests that dexamethasone does not diminish, but may enhance, its cysticidal efficacy, allowing for combined therapy.